ZIPRASIDONE HCL

Indications & Dose:

Management of schizophrenia and other psychotic disorders, and for maintenance of clinical improvement and prevention of relapse during continuation therapy.

• BY MOUTH

Adults: 40 mg twice daily, to be taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as Day 3 of treatment

• BY INTRAMUSCULAR

IM: 10 mg q2hr or 20 mg q4hr; not to exceed 40 mg/day; use IM for up to 3 days, and switch to PO if continuing past this time

Contraindications:

 Known hypersensitivity to ziprasidone or any of the excipients; Known QT interval prolongation including congenital long QT Syndrome; Recent myocardial infarction; Uncompensated heart failure; Cardiac arrhythmias requiring treatment with Class IA and III antiarrhythmic drugs.

Children: Safety and effectiveness in children under 18 years have not been established.

Elderly: Generally, no dosage adjustment is required in elderly patients (65 years and over).

Renal Impairment: No dosage adjustment is required in patients with renal impairment.

Hepatic Impairment: In patients with mild to moderate hepatic insufficiency, lower doses should be considered. There is a lack of experience in patients with

severe hepatic insufficiency and ziprasidone should be used with caution in this group. (See Section Pharmacokinetic Properties.)

Use in Smokers: No dosage adjustment is required in patients who smoke. 

Side Effects:

 The following adverse reactions have been reported during post-marketing experience:

Cardiovascular: postural hypotension.

Heart Rate/Rhythm: tachycardia

Psychiatric: insomnia

Skin and Appendages: rash. 

Cautions:

Precautions:

Interaction:

DRUGS

antihypertensives Additive antihypertensive effects carbamazepine: Possibly decreased blood ziprasidone level CNS depressants: Increased

CNS depression dopamine agonists, levodopa: Decreased therapeutic effects of these drugs drugs that prolong

QT interval (including quinidine, dofetilide, pimozide, sotalol, thioridazine, and sparfloxacin): Increased risk of prolonged QT or QTc interval,

torsades de pointes, and sudden death ketoconazok: Possibly increased blood ziprasidone level 

Warnings:

Adverse Effects:

Lactations:

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: